TABLE 3.
Patient characteristics | No. of isolates | Genotypea |
---|---|---|
Gender | ||
Male | 90 | NA |
Female | 99 | NA |
Data not available | 36 | NA |
Age group (yr) | ||
0–9 | 35 | NA |
10–19 | 19 | NA |
20–29 | 40 | NA |
30–39 | 42 | NA |
40–49 | 23 | NA |
50–59 | 11 | NA |
60–69 | 9 | NA |
70–79 | 7 | NA |
80–89 | 4 | NA |
90–99 | 3 | NA |
Data not available | 32 | NA |
No. of clustersb | ||
1 (household) | 4 | CC/ST30-MRSA-IV |
2 (household) | 3 | CC/ST30-MRSA-IV |
3 (household) | 4 | CC/ST8-MRSA-IV |
4 (household) | 3 | CC/ST8-MRSA-IV |
5 (household) | 4 | CC80-MRSA-IV |
6 (hospital) | 6 | ST772-MRSA-V |
7 (hospital and household)c | 11 | ST772-MRSA-V |
International travel to or country/region of origin | ||
United States | 1 | CC1-MRSA-IV |
3 | ST8-MRSA-IV | |
Africa | 1 | ST8-MRSA-IV |
1 | CC5-MRSA-IV | |
2 | ST30-MRSA-IV | |
1 | CC121-MSSA | |
1 | CC5-MRSA-V | |
The Middle East | 1 | ST80-MRSA-IV |
India | 1 | ST772-MRSA-V |
5 | ST772-MRSA-V | |
Far East Asia | 1 | ST80-MRSA-IV |
1 | ST154-MRSA-IV | |
3 | ST30-MRSA-IV | |
1 | CC121-MSSA | |
1 | ST59-MRSA-V | |
1 | ST8-MRSA-IV | |
Australia | 1 | CC22-MRSA-IV |
1 | ST93-MRSA-IV | |
New Zealand | 1 | ST8-MRSA-IV |
Brazil | 1 | ST8-MRSA-IV |
Czech Republic | 1 | CC1-MRSA-IV |
Undefined (outside of Ireland) | 2 | ST59/952-MRSA-V |
1 | ST22-MRSA-IV | |
1 | CC22-MSSA | |
1 | CC30-MSSA |
NA, not applicable; CC, clonal complex; ST, sequence type.
Isolates were defined as clusters if they were recovered from members of one family/household, within a hospital, or both. Within each cluster, isolates were recovered between 3 months and 2 years apart. Each isolate within a cluster was recovered from a different person or environmental source.
The 11 pvl-positive ST772-MRSA-V isolates in cluster 7 were described previously (31).